PACIRA BIOSCIENCES, INC. Cash and Restricted Cash
PACIRA BIOSCIENCES, INC. (PCRX) had Cash and Restricted Cash of $205.88 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $205.88M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $144.31M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $158.54M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $147.59M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $205.88M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $144.31M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $158.54M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $147.59M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $300.48M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $283.61M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $276.77M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $245.97M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $247.05M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $184.05M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $153.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $99.12M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $86.81M 10-Q · filed 2024-07-30 |
| 2023-03-31 | $35.55M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $104.14M 10-K · filed 2026-02-26 |
| 2022-09-30 | $109.42M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $122.06M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $226.75M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $585.58M 10-K · filed 2025-02-27 |
| 2021-09-30 | $134.04M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $105.77M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $66.70M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $99.96M 10-K · filed 2024-02-29 |
| 2020-09-30 | $125.24M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $78.55M 10-Q · filed 2021-08-03 |
| 2020-03-31 | $54.59M 10-Q · filed 2021-05-04 |
| 2019-12-31 | $78.23M 10-K · filed 2023-02-28 |
| 2019-09-30 | $85.14M 10-Q · filed 2020-10-30 |
| 2019-06-30 | $59.74M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $215.04M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $132.53M 10-Q · filed 2020-10-30 |
| 2018-09-30 | $230.94M 10-Q · filed 2019-11-08 |
| 2017-12-31 | $54.13M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |